Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Reports on HIV/AIDS findings from University of Alabama provide new insights
September 17th, 2008
According to recent research published in the Journal of Virology, "A phase 1 clinical vaccine study of a human immunodeficiency virus type 1 (HIV-1) vaccine regimen comprising a DNA prime formulation (5-valent env and monovalent gag) followed by a 5-valent Env protein boost for seronegative adults was previously shown to induce HIV-1-specific T cells and anti-Env antibodies capable of neutralizing cross-clade viral isolates. In light of these initial findings, we sought to more fully characterize the HIV-1-specific T cells by using polychromatic How cytometry." "Three groups of participants were vaccinated three times with 1.2 mg of DNA administered...
Source: Vaccine Weekly (2008-09-17)
|
